ArticleCancer innovation2022

Pooled analyses of randomized controlled trials on pyrotinib plus capecitabine and a rethink of the first-line options for HER2-positive relapsed or metastatic breast cancer.

Xiuwen Guan et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.